Screener
Bristol-Myers Squibb BMY Accrued Expenses
Accrued Expenses at other companies
Other financials
Where this comes from
Reported directly by Bristol-Myers Squibb in its filing.
Tagged under the XBRL concept us-gaap:OtherLiabilitiesCurrent.
The source filing: Bristol-Myers Squibb’s 10-Q, filed July 30, 2026.
- Filed
- Jul 30, 2026, 11:10 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0000014272-26-000020
| ASSETS | June 30,2026 | December 31,2025 |
|---|---|---|
| Current liabilities: | ||
| Short-term debt obligations | $1,027 | $2,261 |
| Accounts payable | 4,158 | 3,575 |
| Other current liabilities | 13,474 | 17,581 |
| Total Current liabilities | 18,659 | 23,417 |
| Deferred income taxes | 222 | 222 |
| Long-term debt | 42,093 | 42,850 |
| Other non-current liabilities | 4,341 | 5,043 |
Item 1. FINANCIAL STATEMENTS
FAQ
- What is Bristol-Myers Squibb's accrued expenses?
- Bristol-Myers Squibb (BMY) reported accrued expenses of $13.47B in Q2 2026.
- How has Bristol-Myers Squibb's accrued expenses changed year-over-year?
- Bristol-Myers Squibb's accrued expenses decreased by 22.5% year-over-year, from $17.39B to $13.47B.
- What is the long-term trend for Bristol-Myers Squibb's accrued expenses?
- Over 5 years (2020 to 2025), Bristol-Myers Squibb's accrued expenses has grown at a 4.6% compound annual growth rate (CAGR), from $14.03B to $17.58B.
- What does accrued expenses mean?
- Expenses incurred but not yet paid or invoiced — interest accruals, tax accruals, warranty reserves, and other timing differences.
Ask your AI about Bristol-Myers Squibb's accrued expenses.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude